Abstract:High-throughput B-cell sequencing has opened up new avenues for investigating complex mechanisms underlying our adaptive immune response. These technological advances drive data generation and the need to mine and analyze the information contained in these large datasets, in particular the identification of therapeutic antibodies (Abs) or those associated with disease exposure and protection. Here, we describe our efforts to use artificial intelligence (AI)-based image-analyses for prospective classification of Abs based solely on sequence information. We hypothesized that Abs recognizing the same part of an antigen share a limited set of features at the binding interface, and that the binding site regions of these Abs share share common structure and physicochemical property patterns that can serve as a "fingerprint" to recognize uncharacterized Abs. We combined large-scale sequence-based protein-structure predictions to generate ensembles of 3-D Ab models, reduced the Ab binding interface to a 2-D image (fingerprint), used pre-trained convolutional neural networks to extract features, and trained deep neural networks (DNNs) to classify Abs. We evaluated this approach using Ab sequences derived from human HIV and Ebola viral infections to differentiate between two Abs, Abs belonging to specific B-cell family lineages, and Abs with different epitope preferences. In addition, we explored a different type of DNN method to detect one class of Abs from a larger pool of Abs. Testing on Ab sets that had been kept aside during model training, we achieved average prediction accuracies ranging from 71-96% depending on the complexity of the classification task. The high level of accuracies reached during these classification tests suggests that the DNN models were able to learn a series of structural patterns shared by Abs belonging to the same class. The developed methodology provides a means to apply AI-based image recognition techniques to analyze high-throughput B-cell sequencing datasets (repertoires) for Ab classification.

DLAB: deep learning methods for structure-based virtual screening of antibodies

Deep Geometric Framework to Predict Antibody-Antigen Binding Affinity

Sequence-based deep learning antibody design for in silico antibody affinity maturation

Improving B-cell Epitope Prediction and Its Application to Global Antibody-Antigen Docking.

Antibody Representation Learning for Drug Discovery

Accurate prediction of antibody function and structure using bio-inspired antibody language model

BigBind: Learning from Nonstructural Data for Structure-Based Virtual Screening

Toward enhancement of antibody thermostability and affinity by computational design in the absence of antigen

Towards the accurate modelling of antibody-antigen complexes from sequence using machine learning and information-driven docking

Active learning for affinity prediction of antibodies

Structural modeling of antibody variable regions using deep learning—progress and perspectives on drug discovery

AI-Augmented Physics-Based Docking for Antibody-Antigen Complex Prediction

An artificial intelligence accelerated virtual screening platform for drug discovery

Deep Learning in Preclinical Antibody Drug Discovery and Development.

Using the antibody-antigen binding interface to train image-based deep neural networks for antibody-epitope classification

AlphaBind, a Domain-Specific Model to Predict and Optimize Antibody-Antigen Binding Affinity

Advances in Protein-Ligand Binding Affinity Prediction via Deep Learning: A Comprehensive Study of Datasets, Data Preprocessing Techniques, and Model Architectures

Structure-based, deep-learning models for protein-ligand binding affinity prediction

Exploration on Learning Molecular Docking with Deep Learning Models

Enhanced antibody-antigen structure prediction from molecular docking using AlphaFold2